Mylab Partners with Ekincare to Promote Influenza Nasal Vaccine ‘NASOVAC-S4’

The collaboration seeks to incorporate NASOVAC-54 into their employee wellness programs. By making this influenza vaccine accessible to their employees, corporations can take proactive measures to safeguard their workforce's health.

Pune-based biotech company, Mylab has joined hands with Ekincare, a corporate wellness and health benefits platform, to promote NASOVAC-S4, an Influenza nasal vaccine among corporate entities.

Developed by the Serum Institute of India (SII), NASOVAC-S4 is a nasal spray vaccine that helps protect against influenza, commonly known as the flu. The novel vaccine contains four specific strains of the influenza virus, two of Type A (H1N1 and H3N2) and two of Type B1, which provide protection against multiple types of flu.

The collaboration seeks to incorporate NASOVAC-54 into their employee wellness programs. By making this influenza vaccine accessible to their employees, corporations can take proactive measures to safeguard their workforce's health.

Sharing his views, Hasmukh Rawal, MD and cofounder, Mylab, said, "We are excited to join forces with Ekincare to promote NASOVAC-S4. This collaboration underscores our commitment to enhancing public health by offering advanced healthcare solutions This vaccine holds the promise of transforming corporate influenza vaccination campaigns, and we are delighted to be a part of this endeavour."

Founded in 2014 by Kiran Kalakuntla and Srikanth Samudrala, Ekincare is a tech-enabled healthcare benefits platform that helps organisations monitor their employees’ health and wellness. Further, the Hyderabad-based company aims to leverage technology to make preventive healthcare accessible and convenient.

In terms of future plans, Ekincare intends to continue expanding its services and improving its technology to provide better healthcare solutions. Some of their clients include LinkedIn, Nike, Lenovo, S&P Global, and eBay, to name a few.

Commenting on the partnership, Kiran Kalakuntla, CEO and cofounder, Ekincare, said, "The health of employees is a top priority for any organisation. Influenza can have a significant impact on a company's operations. By offering NASOVAC-S4 to our corporate and health insurance partners, we aim to provide an accessible and effective solution to protect employees from the flu. We are delighted to collaborate with Mylab to make this innovative vaccine available to businesses across India."

Mylab, on the other hand, was founded in 2016 by Hasmukh Rawal and Sujit Jain. The Pune-based biotech company is dedicated to developing modern solutions for medical diagnostics. They aim to make healthcare more affordable and accessible through their products.

Moreover, Mylab was the first Indian company to receive commercial approval from the Central Drugs Standard Control Organisation (CDSCO) for its COVID-19 RT-PCR tests. Going forward, Mylab plans to continue its research and development in medical diagnostics to address various health issues.

In September this year, Mylab launched the newborn screening point of care device ‘MyNeoShield’. This device promises swifter, more accessible, and cost-effective screening methods aimed at saving lives and preventing lifelong illnesses. It facilitates all seven tests commonly performed in newborn screening worldwide.